Cytotoxic therapy induces macrophage recruitment, as well as CSF1 and IL-34 mRNA expression. Cytotoxic therapy induces macrophage recruitment, as well.

Slides:



Advertisements
Similar presentations
Supplemental Figures CAN Sahu et al.. Fig Supplementary S1 Figure S1. Chemotherapy agents generate PAF-R agonist formation in human SK23MEL melanoma.
Advertisements

Glioma-derived soluble factor(s) enhance IL-10 signaling.
Supplementary Figure S1.
Cell Physiol Biochem 2013;32: DOI: /
A Novel Cinnamide YLT26 Induces Breast Cancer Cells Apoptosis via ROS-Mitochondrial Apoptotic Pathway in Vitro and Inhibits.
Figure 3. Sensitivity of the gastric carcinoma cell line N87 for trastuzumab in comparison with the breast cancer cell line SKBR-3. (A) Dose–response curves.
Interleukin-5–producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy by Frédéric Van Gool, Ari B. Molofsky, Malika.
Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.
Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.
Volume 9, Issue 6, Pages (June 2004)
IL-6 is dispensable for the suppressive activity of MDSC on primary CD4+ T-cell activation. IL-6 is dispensable for the suppressive activity of MDSC on.
B7-H4 expression correlates with MHC-I expression and improved prognosis in patients with breast cancer. B7-H4 expression correlates with MHC-I expression.
Peritumoral injections of poly(I:C) induce type I IFN–dependent cytotoxic immunity and delay the growth of primary and transplanted Hgf-Cdk4R24C melanomas.
Volume 140, Issue 2, Pages e4 (February 2011)
CHK1 downregulation upon ERG overexpression.
Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.
Microarray analysis of phospho-Twist1–responsive genes.
Fig. 3 In situ vaccination with CpG and anti-OX40 is therapeutic in a spontaneous tumor model. In situ vaccination with CpG and anti-OX40 is therapeutic.
Cytotoxic therapy induces CSF1-dependent macrophage recruitment.
Volume 13, Issue 12, Pages (December 2015)
Leukocytes in human PDAC
A, left: indicated MEFs were transfected as described in the Methods section. A, left: indicated MEFs were transfected as described in the Methods section.
Volume 21, Issue 11, Pages (November 2013)
Epithelial loss of TβRII results in increased Th17 cell development.
Volume 19, Issue 1, Pages (April 2017)
2aG4 directly induces monocytic MDSCs to differentiate into dendritic cells and macrophages by binding to phosphatidylserine on their cell surface. 2aG4.
Volume 16, Issue 2, Pages (August 2009)
Existence of a nuclear NFATc1–STAT3 complex in pancreatic cancer.
Targeting ubiquitin-activating enzyme induces ER stress–mediated apoptosis in B-cell lymphoma cells by Scott Best, Taylor Hashiguchi, Adam Kittai, Nur.
Volume 12, Issue 4, Pages (July 2015)
Volume 19, Issue 1, Pages (April 2017)
MI-773 reduces the fraction of CSCs and prevents recurrence in ACC xenograft tumors. MI-773 reduces the fraction of CSCs and prevents recurrence in ACC.
Activity of MAC-321 (i. v. and p. o
Therapy-induced senescence of primary cells.
ONC201 activates the ISR. ONC201 activates the ISR. (A) Western blotting analysis for ATF4, CHOP, ATF3, and TRB3 on lysates from HCT116 cells cultured.
Fig. 6. Nontaxane chemotherapies induce TMEM-dependent prometastatic changes in the breast cancer microenvironment. Nontaxane chemotherapies induce TMEM-dependent.
PTX in combination with PLX397 induces antitumor T-cell response.
Volume 21, Issue 11, Pages (November 2013)
CD151 effects on mammary cell morphology and adhesion.
Overexpression of IL-27 upregulates expression of multiple IR by T cells in vivo. Overexpression of IL-27 upregulates expression of multiple IR by T cells.
Increased CCL5 expression, infiltration of Treg cells, and apoptosis of CD8+ T cells in human colorectal tissues. Increased CCL5 expression, infiltration.
CD49b+ cells from tumor-bearing mice are more prone to conversion into MDSCs compared with naive CD49b+ cells. CD49b+ cells from tumor-bearing mice are.
Volume 2, Issue 2, Pages (August 2002)
coTCRcys-transduced T cells control tumor growth in vivo.
Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection by Maria Moeller, Nicole M. Haynes, Michael.
Overexpression of DDB2 reduces invasive abilities in lungs of aggressive breast tumor cells. Overexpression of DDB2 reduces invasive abilities in lungs.
Active AR signaling in enzalutamide-resistant xenograft tumors.
The antitumor and antimetastatic properties of PF in the MX1 orthotopic model. The antitumor and antimetastatic properties of PF in the.
Orthotopic PDAC growth is regulated by B cells and FcRγ-positive myeloid cells. Orthotopic PDAC growth is regulated by B cells and FcRγ-positive myeloid.
Pharmacodynamic evaluation of VT-464 and ABI in MR49F xenograft model.
M-CSFR inhibition decreases tumor-associated macrophages in mesothelioma and improves the DC therapy induced CD8+ T-cell phenotype. M-CSFR inhibition decreases.
SY-1425 induces maturation in RARA-high AML
NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.
EGFR signaling regulates transcription of PDGFRβ gene.
Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.
The CD8+ cytotoxic T-cell response in Ron TK−/− hosts in response to tumors is necessary and sufficient to block metastasis. The CD8+ cytotoxic T-cell.
Anti-CD40 activates TAMs and recruits inflammatory monocytes.
The effects of AZD1775 and olaparib on DNA damage response signaling.
Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Combination of R848 and anti-CD200R affects activation of tumor-infiltrating.
Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.
Fig. 8. TIE2 inhibitor rebastinib eliminates the prometastatic effects of paclitaxel. TIE2 inhibitor rebastinib eliminates the prometastatic effects of.
Antibody-mediated blockade of the immune-inhibitory PD-1–PD-L1 signaling pathway prolongs survival in poly(I:C)-treated mice. Antibody-mediated blockade.
Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. A,
PARP1 suppresses the transcription of PD-L1 in cancer cells.
PLK1 is a crucial downstream effector of PDK1 for MYC activation and cell survival. PLK1 is a crucial downstream effector of PDK1 for MYC activation and.
In vivo inhibition of IL-17 abrogates tumor-promoting effect of myeloid cells. In vivo inhibition of IL-17 abrogates tumor-promoting effect of myeloid.
FGFR2 amplification in primary human gastric tumors predicts for response to NVP-BGJ398. FGFR2 amplification in primary human gastric tumors predicts for.
In vivo effect of KIN-193 on PTEN-deficient tumors.
Fig. 5. Paclitaxel promotes breast cancer cell dissemination and metastasis in a MENA-dependent manner. Paclitaxel promotes breast cancer cell dissemination.
Parthenolide inhibits tumor promotion and increases p21 expression in vivo. Parthenolide inhibits tumor promotion and increases p21 expression in vivo.
Presentation transcript:

Cytotoxic therapy induces macrophage recruitment, as well as CSF1 and IL-34 mRNA expression. Cytotoxic therapy induces macrophage recruitment, as well as CSF1 and IL-34 mRNA expression. A, macrophage percentage in fresh human primary breast cancer tissues, depicted as mean of CD45+CD11b+CD14+ macrophages as a percentage of total cells (analyzed by flow cytometry). “Neo-adjuvant” denotes patients who received chemotherapy prior to surgical resection of their primary breast cancer, as opposed to those who did not, denoted as “untreated”; *, statistically significant differences (P = 0.004) between the 2 groups. B, PTX-induced CSF1 mRNA expression regulates tumor infiltration of macrophages and limits PTX response. (i), TAM percentage in mammary tumors of MMTV-PyMT mice following PTX treatment with mean number of CD45+Ly6G−Ly6C−CD11b+F4/80+ TAMs as a percentage of total cells shown (analyzed by flow cytometry); (ii), primary tumor growth reduced by treatment with PTX. The 85-day-old MMTV-PyMT mice were treated with PTX and total tumor burden per animal was assessed every 5 days until endpoint. Treatment schematic is depicted at top, and data are displayed as mean tumor burden ±SEM; *, statistically significant differences between controls and PTX-treated mice (>8 mice/group). C, expression of monocyte/macrophage chemoattractants following chemotherapy. Quantitative reverse transcriptase PCR (qRT-PCR) analyses of CSF1, MCP1, MCP2, MCP3, and IL34 expression in MMTV-pMECs–derived MECs treated with PTX for 24 hours ex vivo, expressed as mean fold change, compared with controls. Samples were assayed in triplicate for each tested condition; *, statistically significant differences between control and PTX-treated groups. D, Dose-dependent expression of CSF1 following chemotherapy or radiation therapy. qRT-PCR analysis of mRNA expression in MMTV-PyMT–derived pMECs 24 hours after treatment with either cisplatin (CDDP), PTX, or a single dose of ionizing radiation, expressed as mean fold change, compared with control ±SEM. Drug and radiation doses are shown. Samples were assayed in triplicate for each tested condition; *, statistically significant differences between control and the indicated treatment. E, CSF1 expression induced by chemotherapy in human breast carcinoma cell lines. qRT-PCR analysis of mRNA expression in BT474, MDA-MB-435, SKBR3, T47D, MCF7, and MDA-MB-231 at 24 hours after treatment with either CDDP or PTX, expressed as mean fold change, compared with vehicle-treated cells ±SEM. Chemotherapeutic doses are denoted. Samples were assayed in triplicate for each condition; *, statistically significant differences between control and indicated treatment. F, CSF1 expression induced by cytotoxic therapy in MMTV-PyMT mammary tumors. qRT-PCR analysis of mRNA expression isolated from normal mammary tissue or MMTV-PyMT mammary tumors from mice treated with either PTX (10 mg/kg) every 5 days, or ionizing radiation (single dose of 8 Gy), expressed as mean fold change, compared with vehicle-treated tumors (4 mice/group). SE is depicted; *, statistically significant differences (P < 0.05, Mann-Whitney) for all gene expression analyses (C–F). David G. DeNardo et al. Cancer Discovery 2011;1:54-67 ©2011 by American Association for Cancer Research